ERBB2 and breast cancer: Proteomic and phosphoproteomic profiling of pre-treatment biopsies of patients with early-stage HER2+ BC were performed to identify multiple cellular mechanisms that precondition tumors to resist therapy by trastuzumab, pertuzumab and chemotherapy.